Carregant...
When the dust settles: what did we learn from the bexarotene discussion?
With 27 million people affected by Alzheimer’s disease (AD), any proposal of a novel avenue for drug development is hot news. When Cramer and colleagues proposed last year that they could tackle AD pathology in an AD mouse model with bexarotene, a drug already in use in the clinic for other diseases...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3979032/ https://ncbi.nlm.nih.gov/pubmed/24229456 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/alzrt218 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|